mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat
详细信息 查看全文
- 作者：Xingang Penga ; 1 ; pengxinggang26@sina.com" class="auth_mail" title="E-mail the corresponding author ; Donghui Zhangb ; 1 ; zhangdonghuiyx@sina.com" class="auth_mail" title="E-mail the corresponding author ; Zhengling Lic ; lizhenglingzz@sina.com" class="auth_mail" title="E-mail the corresponding author ; Meili Fub ; fumeilidrlinyi@tom.com" class="auth_mail" title="E-mail the corresponding author ; Haiyan Liud ; liuhaiyanlinyi5@sina.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Hepatocellular carcinoma ; HDACs ; Resminostat ; mTOR ; Mitochondrial apoptosis pathway ; Chemo-sensitization
- 刊名：Biochemical and Biophysical Research Communications
- 出版年：2016
- 出版时间：2 September 2016
- 年：2016
- 卷：477
- 期：4
- 页码：556-562
- 全文大小：1019 K
文摘
- listitem" id="list_ulist0010">
- •
AZD-2014 potentiates resminostat’s cytotoxicity against HCC cells.
- •
AZD-2014 facilitates resminostat-induced HCC cell apoptosis.
- •
AZD-2014 augments resminostat-induced mitochondrial apoptosis pathway activation.
- •
mTOR shRNA or kinase-dead mutation significantly sensitizes HCC cells to resminostat.